questionText: To ask the Secretary of State for Health and Social Care, what data his Department and the Medicines and Healthcare products Regulatory Agency holds on how many and what proportion of patients develop withdrawal symptoms, including dopamine agonist withdrawal syndrome, when dopamine agonists are reduced or stopped in routine clinical practice in the last five years.
answerText: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
heading: Drugs: Side Effects